Menu
A Phase II, Open Label, Two-Arm Study of Therapeutic Iobenguane (I131) as Single Agent or in Combination with Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects (OPTIMUMTM TRIAL)
The study is currently running across the US and the 20 trial sites listed below are open to enroll more HRNB patients. Click here to register to connect with the clinical team of your choice.
To determine the efficacy and safety of I-131 MIBG treatment in combination with vorinostat in subjects with iobenguane avid, recurrent or progressive high-risk neuroblastoma.
The study is conducted in the United States and will include up to 70 high-risk neuroblastoma patients. Eligible patients will receive up to two cycles of vorinostat, once daily for 14 days, and I-131 MIBG treatment (as a single infusion per cycle).
Participation in the study may involve up to 14 visits over a 2 1/2-year period, depending on the number of treatment cycles received and the response to treatment.
Address: 450 Brookline Ave, Boston, MA 02215
Contact: Catherine M Clinton, MS
Phone: 617-632-5556
Address: 3401 Civic Center Blvd, Philadelphia, PA 19104
Contact: Yael Mosse, MD
Phone: 215-590-0965
Address: One Children’s Hospital Drive, 4401 Penn Ave, Pittsburgh, PA 15224
Contact: Doreen Snelsire
Phone: 412-692-8864
Address: 1001 Blythe Blvd, Charlotte, NC 28203
Contact: Katherine Farmer
Phone: 704-641-7350
Address: 6535 Nemours Parkway, Orlando, FL 32827
Contact: Manisha M Bansal, MD
Phone: 904-697-3793
Address: 3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
Contact: Lori Backus
Phone: 513-636-2047
Address: 1675 Highland Ave, Madison, WI 53792
Contact: Jenny Weiland
Phone: 608-890-8070
Address: 5841 S Maryland Ave, Chicago, IL 60637
Contact: Melissa Z Marx, MPH
Phone: 773-702-2927
Address: 200 Hawkins Drive, Iowa City, IA 52242
Contact: Roxanne Mitten
Phone: 319-356-1212
Address: One Children’s Place, St. Louis, MO 63110
Contact: Sally Jones, MA, CCRP
Phone: 314-454-4353
Address: 425 East River Parkway, Minneapolis, MN 55455
Contact: Ashley Schempp, MPH
Phone: 612-625-9340
Address: 801 7th Ave, Fort Worth, TX 76104
Contact: Juli Ramirez
Phone: 682-885-2580
Address: 1935 Medical District Drive, Dallas, TX 75235
Contact: Beverly Kleiber, PhD, CCRP
Phone: 246-456-1003
Address: 6621 Fannin St, Houston, TX 77030
Contact: Akudo Anyanwu
Phone: 832-824-4167
Address: 4090 Briargate Parkway, Colorado Springs, CO 80920
Contact: Astrid Eder
Phone: 720-777-8531
Address: 1825 Fourth St., San Francisco, CA 94158
Contact: Debbie Lara
Phone: 415-476-2218
Address: 4800 Sand Point Way NE, Seattle, WA 98105
Contact: Christine Goetz, BA, CCRC
Phone: 206-884-1149
Address: 269-01 76th Ave, Queens, NY 11040
Contact: Eva Atsidaftos
High-risk neuroblastoma is a difficult to treat childhood cancer and those children with resistant or relapsed disease, after current standard of care is exhausted, have poor prognosis.
Jubilant Radiopharma is proud to be a leader in the development of therapeutics intended to treat rare and serious conditions including neuroblastoma. These efforts are aligned with the value that nuclear medicine can bring to improve precise, patient-focused treatment.
NOTE: Therapeutic MIBG labeled with I-131 is not approved by the USFDA or Health Canada
For more information, scan the QR code or refer to ClinicalTrials.gov
Identifier: NCT03561259